By Laura Osman in Ottawa
Health Canada has approved a new COVID-19 vaccine from Moderna that targets both the original strain of the novel coronavirus and the specific Omicron variant.
The new shots approved by Health Canada, called bivalent vaccines, are designed to recognize specific mutations in the spike protein of the Omicron BA.1 subvariant.
Shipments of the vaccine are expected to arrive in the next few days, and there will be enough supply for all Canadians 18 and older to get a dose this fall and winter, officials said.
“With the Omicron variant now circulating, we know that the existing vaccines can be less effective,” said Dr. Supriya Sharma, Health Canada’s chief medical adviser, during an online news conference on Thursday.
In a decision posted on Health Canada’s website, the regulator says data show the new vaccine induces a similar immune response to the original strain of the COVID-19 virus and significantly higher responses to the Omicron BA.1 variant, when compared with the earlier version of the Moderna vaccine.
The United Kingdom approved Moderna’s new vaccine two weeks ago, and the United States Food and Drug Administration gave Moderna and Pfizer-BioNTech’s Omicron-fighting shots the green light earlier this week.
The version approved in the U.S. targets newer and more prevalent strains of the Omicron variant than the one submitted for approval in Canada.
“While the vaccine was designed to more specifically target the Omicron BA.1 subvariant, we know that this vaccine also generates a good immune response against Omicron BA.4 and BA.5 subvariants that have more recently emerged,” Sharma said.
The Omicron variant arrived in Canada in late 2021 and has spread aggressively ever since. Subvariants of Omicron are now by far the most common strains of the virus.
The BA.5 subvariant currently represents approximately 82 per cent of the virus circulating in Canada, Public Health Agency of Canada data show. BA.4 makes up nearly 12 per cent and BA.1 represents only 0.1 per cent.
Health Canada has specifically asked Moderna and Pfizer-BioNTech to request approval for vaccines that target the BA.4 and BA.5 subvariants, and is expecting applications from both companies within the next few weeks.
The National Advisory Committee on Immunization recommends that people over the age of 18 should be offered the Omicron booster.
If the newer shot isn’t available, the committee says people should instead opt for a booster shot of the original COVID-19 vaccine to ensure timely protection.
NACI generally recommends that people wait six months after their last vaccine or a COVID-19 infection before getting another shot.
The committee also says the Omicron shot should be considered for children aged 12 to 17 who are immunocompromised, though the vaccine is not approved for use in kids and the expert recommendation makes clear that the relative risks and benefits remain uncertain.
Canada has already purchased 12 million doses of Moderna’s version of the Omicron vaccine,which includes converting some existing orders for the original Moderna vaccine so that the newly adapted version will be delivered instead.
Dr. Howard Njoo, the deputy chief public health officer, said shipments will start to arrive over the next few days.
“Based on provincial and territorial projections, there will be enough supply of the Moderna Spikevax bivalent COVID-19 vaccine in Canada for everyone 18 years of age and older this fall and winter,” Njoo said at the press conference.
Health Minister Jean-Yves Duclos is expected to hold a press conference Thursday afternoon to speak to the importance of getting a booster shot.
Duclos has already signalled that a swift rollout of the vaccines will be important to fend off another potentially large wave of infections in the fall.
While more than 90 per cent of adults have received two doses of an approved COVID-19 vaccine in Canada, only about 59 per cent have opted for a booster dose as of Aug. 14, Public Health Agency of Canada data show.
Banner image: Health-care worker Thi Nguyen administers Pfizer-BioNtech COVID-19 vaccine to a patient at a clinic in Ottawa on March 30, 2021. Health Canada has approved a new COVID-19 vaccine from Moderna that targets both the original strain of the novel coronavirus and the Omicron variant. THE CANADIAN PRESS/Sean Kilpatrick
This report by The Canadian Press was first published Sept. 1, 2022.